Skip to main content
. Author manuscript; available in PMC: 2017 Sep 5.
Published in final edited form as: Value Health. 2014 May 5;17(4):424–432. doi: 10.1016/j.jval.2014.01.008

Table 2.

Results of network meta-analyses.

Comparison Analysis 1* Analysis 2* Analysis 3*



OR (95% CrI) RRR (95% CrI) P(better) P(best) OR (95% CrI) RRR (95% CrI) P(better) P(best) OR (95% CrI) RRR (95% CrI) P(better) P(best)
vs placebo
ALEN 0.81 (0.61– 1.00) 0.18 (0.00– 0.37) 97% 3% 0.75 (0.59–0.92) 0.23 (0.07–0.39) > 99% 4% 0.85 (0.47–1.44) 0.14 (−0.39 to 0.51) 75% 6%
IBAN 1.12 (0.70– 1.81) −0.11 (–0.67 to 0.28) 29% 1% 1.08 (0.46–3.28) −0.07 (–1.66 to 0.51) 42% 4% 1.17 (0.37–2.50) −0.16 (−1.20 to 0.61) 33% 5%
RISED 0.75 (0.54– 0.93) 0.23 (0.07– 0.43) 99% 7% 0.76 (0.57–0.96) 0.22 (0.04–0.40) > 99% 4% 0.69 (0.36–1.09) 0.29 (−0.08 to 0.62) 95% 19%
BAZ 0.44 (0.21– 0.92) 0.53 (0.08– 0.77) 98% 90% 0.50 (0.36–0.78) 0.47 (0.20–0.61) > 99% 89% 0.50 (0.24–1.02) 0.48 (−0.01 to 0.74) 97% 70%
BAZ vs
ALEN 0.55 (0.26– 1.21) 0.43 (−0.19 to 0.72) 94% 0.67 (0.45–1.11) 0.31 (−0.10 to 0.52) 95% 0.59 (0.24–1.49) 0.39 (−0.46 to 0.74) 88%
IBAN 0.40 (0.17– 0.94) 0.58 (0.05–0.81) 98% 0.47 (0.15–1.17) 0.50 (−0.16 to 0.81) 95% 0.43 (0.15–1.56) 0.55 (−0.52 to 0.83) 92%
RISED 0.59 (0.28– 1.32) 0.39 (−0.29 to 0.70) 91% 0.67 (0.45–1.12) 0.31 (−0.11 to 0.53) 95% 0.73 (0.30–1.84) 0.26 (−0.78 to 0.68) 76%

AD, aggregated data; ALEN, alendronate; BAZ, bazedoxifene; FRAX, Fracture Risk Assessment Tool; IBAN, ibandronate; IPD, individual patient data; OR, odds ratio; RISED, risedronate; RRR, relative risk reduction; P(better), probability the intervention is better than comparator.

*

Analysis 1: Unadjusted comparison based on AD of bisphosphonates and subgroup with a FRAX score of ≥20% for bazedoxifene (N = 24,058); analysis 2: Meta-regression controlling for baseline risk (placebo response) based on AD of bisphosphonates and all FRAX subgroups for bazedoxifene (N = 29,267); analysis 3: Meta-regression controlling for baseline risk (placebo response in bisphosphonate trials and FRAX for bazedoxifme trial) based on AD of bisphosphonates and IPD for bazedoxifene (N = 29,267).

RRR = 1 – relative risk. The relative risk and OR will be similar when the incidence of an event is low, such as with nonvertebral fractures.